70 related articles for article (PubMed ID: 12599454)
21. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
[TBL] [Abstract][Full Text] [Related]
22. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
Uno H; Koide T; Kuriyama M; Ban Y; Deguchi T; Kawada Y
Hinyokika Kiyo; 1999 Jul; 45(7):457-61. PubMed ID: 10466060
[TBL] [Abstract][Full Text] [Related]
23. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.
Oesterling JE; Jacobsen SJ; Chute CG; Guess HA; Girman CJ; Panser LA; Lieber MM
JAMA; 1993 Aug; 270(7):860-4. PubMed ID: 7688054
[TBL] [Abstract][Full Text] [Related]
24. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer.
Cutting CW; Hunt C; Nisbet JA; Bland JM; Dalgleish AG; Kirby RS
BJU Int; 1999 Jun; 83(9):996-9. PubMed ID: 10368242
[TBL] [Abstract][Full Text] [Related]
25. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
[TBL] [Abstract][Full Text] [Related]
26. Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study.
Oliver SE; Gunnell D; Donovan J; Peters TJ; Persad R; Gillatt D; Pearce A; Neal DE; Hamdy FC; Holly J
Int J Cancer; 2004 Mar; 108(6):887-92. PubMed ID: 14712493
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
[TBL] [Abstract][Full Text] [Related]
28. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
29. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
30. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
31. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
Safarinejad MR; Shafiei N; Safarinejad S
Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
[TBL] [Abstract][Full Text] [Related]
32. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
33. Low serum insulin-like growth factor 1 (IGF-1): a significant association with prostate cancer.
Baffa R; Reiss K; El-Gabry EA; Sedor J; Moy ML; Shupp-Byrne D; Strup SE; Hauck WW; Baserga R; Gomella LG
Tech Urol; 2000 Sep; 6(3):236-9. PubMed ID: 10963500
[TBL] [Abstract][Full Text] [Related]
34. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
Zhigang Z; Jieming L; Su L; Wenlu S
J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
[TBL] [Abstract][Full Text] [Related]
35. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
36. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study.
Friedlander TW; Weinberg VK; Small EJ; Sharib J; Harzstark AL; Lin AM; Fong L; Ryan CJ
Urol Oncol; 2012; 30(4):408-14. PubMed ID: 20884247
[TBL] [Abstract][Full Text] [Related]
37. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
Kaynar M; Yildirim ME; Gul M; Kilic O; Ceylan K; Goktas S
Cancer Biomark; 2015; 15(3):317-23. PubMed ID: 25586096
[TBL] [Abstract][Full Text] [Related]
38. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia.
Bogdanowicz JF; Bentvelsen FM; Oosterom R; Schroeder FH
Scand J Urol Nephrol Suppl; 1991; 138():97-103. PubMed ID: 1723815
[TBL] [Abstract][Full Text] [Related]
40. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]